Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)The purpose of this study is to test the safety and efficacy of RBX2660 in preventing recurrent episodes of CDI measured at 8 weeks after treatment. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2)The purpose of this study is to compare ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection The purpose of this study is to assess safety and efficacy of SER-109 in reducing recurrence of Clostridium difficile infection (CDI) in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in Study SERES-012. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionThis study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension). Closed for Recruitment Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 18 and above
Clostridium Difficile Vaccine Efficacy Trial (Clover)The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection.Closed for Recruitment Principal Investigator Titus WongBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 50 and above
